Company profile: Apellis
1.1 - Company Overview
Company description
- Provider of novel therapeutics and drug delivery technologies for chronic inflammatory diseases, with approved treatments SYFOVRE for geographic atrophy (a form of age-related macular degeneration) and EMPAVELI for paroxysmal nocturnal hemoglobinuria; conducts clinical trials for IC-MPGN and C3G, HSCT-TMA, and CAD; and offers compassionate use and early access programs for investigational therapies.
Products and services
- EMPAVELI: Delivers an approved treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disease, supplying therapy specifically for PNH patients
- SYFOVRE: Offers an approved treatment for Geographic Atrophy (GA), a form of age-related macular degeneration leading to vision loss
- Compassionate Use and Early Access Programs: Supplies investigational-access programs enabling critically ill patients not eligible for clinical trials to access investigational therapies.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Apellis
Rigel Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rigel Pharmaceuticals company profile →
Reneo Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapies in development for rare genetic mitochondrial and orphan metabolic diseases. Develops mavodelpar (REN001) for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD), with a global Phase 2b trial in PMM and completed exploratory Phase 1b trials in LC-FAOD and McArdle disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reneo Pharmaceuticals company profile →
Pathios Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small molecule GPR65 inhibitors to develop therapies for autoimmune diseases and cancer, targeting the pH-sensing GPCR GPR65 to counteract immunosuppressive polarization of immune cells. Offerings include PTT-4256, an orally bioavailable, highly potent and selective GPR65 inhibitor for cancer, and CNS-optimized GPR65 inhibitors for malignant brain tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pathios Therapeutics company profile →
Principia Biopharma
HQ: United States
Website
- Description: Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Principia Biopharma company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Apellis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Apellis
2.2 - Growth funds investing in similar companies to Apellis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Apellis
4.2 - Public trading comparable groups for Apellis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →